S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
NASDAQ:FOLD

Amicus Therapeutics (FOLD) Stock Price, News & Analysis

$13.29
+0.47 (+3.67%)
(As of 03/1/2024 ET)
Today's Range
$12.95
$13.60
50-Day Range
$12.03
$14.52
52-Week Range
$9.70
$14.57
Volume
2.76 million shs
Average Volume
3.11 million shs
Market Capitalization
$3.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

Amicus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
50.5% Upside
$20.00 Price Target
Short Interest
Bearish
9.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.28
Upright™ Environmental Score
News Sentiment
0.50mentions of Amicus Therapeutics in the last 14 days
Based on 24 Articles This Week
Insider Trading
Selling Shares
$3.67 M Sold Last Quarter
Proj. Earnings Growth
1,233.33%
From $0.03 to $0.40 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.17 out of 5 stars

Medical Sector

173rd out of 951 stocks

Pharmaceutical Preparations Industry

73rd out of 430 stocks


FOLD stock logo

About Amicus Therapeutics Stock (NASDAQ:FOLD)

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

FOLD Stock Price History

FOLD Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Q4 2023 Amicus Therapeutics Inc Earnings Call
Buy Rating Affirmed for Amicus with Strong Growth and Promising Outlook
See More Headlines
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
3/03/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
484
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$20.00
High Stock Price Target
$22.00
Low Stock Price Target
$19.00
Potential Upside/Downside
+50.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-236,570,000.00
Pretax Margin
-37.59%

Debt

Sales & Book Value

Annual Sales
$399.36 million
Book Value
$0.54 per share

Miscellaneous

Free Float
287,088,000
Market Cap
$3.93 billion
Optionable
Optionable
Beta
0.77

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report














FOLD Stock Analysis - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FOLD shares.
View FOLD analyst ratings
or view top-rated stocks.

What is Amicus Therapeutics' stock price target for 2024?

4 Wall Street analysts have issued 12-month target prices for Amicus Therapeutics' stock. Their FOLD share price targets range from $19.00 to $22.00. On average, they predict the company's share price to reach $20.00 in the next year. This suggests a possible upside of 50.5% from the stock's current price.
View analysts price targets for FOLD
or view top-rated stocks among Wall Street analysts.

How have FOLD shares performed in 2024?

Amicus Therapeutics' stock was trading at $14.19 at the beginning of 2024. Since then, FOLD stock has decreased by 6.3% and is now trading at $13.29.
View the best growth stocks for 2024 here
.

Are investors shorting Amicus Therapeutics?

Amicus Therapeutics saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 26,780,000 shares, an increase of 9.8% from the January 31st total of 24,400,000 shares. Based on an average daily volume of 3,120,000 shares, the days-to-cover ratio is currently 8.6 days.
View Amicus Therapeutics' Short Interest
.

When is Amicus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our FOLD earnings forecast
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) released its quarterly earnings data on Wednesday, November, 8th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The biopharmaceutical company earned $103.50 million during the quarter, compared to analyst estimates of $102.30 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 119.46% and a negative net margin of 37.96%. Amicus Therapeutics's revenue was up 26.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.12) earnings per share.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics issued an update on its FY 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $399.4 million-$399.4 million, compared to the consensus revenue estimate of $396.5 million.

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.72%), Perceptive Advisors LLC (9.57%), Palo Alto Investors LP (3.54%), Fiera Capital Corp (1.73%), Northern Trust Corp (0.97%) and Norges Bank (0.86%). Insiders that own company stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends
.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FOLD) was last updated on 3/3/2024 by MarketBeat.com Staff